Phenotypes associated with this allele

• Allele Symbol: Il19^tm2Vlcg
• Allele Name: targeted mutation 2, Velocigene
• Allele ID: MGI:5763407
• Summary: 1 genotype

Jump to	Allelic Composition	Genetic Background	Genotype ID
hm1	Il19^tm2Vlcg/Il19^tm2Vlcg	B6.Cg-Il19^tm2Vlcg	MGI:5763467

Genotype
MGI:5763467

hm1

• Allelic Composition: Il19^tm2Vlcg/Il19^tm2Vlcg
• Genetic Background: B6.Cg-Il19^tm2Vlcg

• ♀: phenotype observed in females
• ♂: phenotype observed in males
• N: normal phenotype

mortality/aging

increased susceptibility to colitis induced morbidity/mortality ( J:229575 )

• in DSS-treated mice

immune system

immune system phenotype ( J:229575 )

N • mice exhibit normal lymphoid and myeloid cellular composition in the thymus, spleen, and lymph node and no spontaneous colitis or intestinal inflammation up to 18 months of age

N • dendritic cells exhibit normal response to LPS

increased susceptibility to induced colitis ( J:229575 )

• after 5 days, DSS-treated mice exhibit increased mortality, weight loss, bleeding, diarrhea, general loss of architecture, inflammatory cell infiltration, and cytokine production (IL1B, IL6, IL12, IFN-gamma, TNF) compared with wild-type mice

• after 30 days, mice subjected to chronic DDS-induced colitis exhibit decreased B cell infiltration, colon length and cytokine production (IL10, KC, IL6 and IL13) compared with wild-type mice

• however, chronically DSS-treated mice exhibit normal Th1 response

increased susceptibility to colitis induced morbidity/mortality ( J:229575 )

• in DSS-treated mice

increased interferon-gamma secretion ( J:229575 )

• from cultured distal colons of DSS-treated mice after 5 days

increased interleukin-1 beta secretion ( J:229575 )

• from cultured distal colons of DSS-treated mice after 5 and 30 days

• from macrophages following LPS stimulation

decreased interleukin-10 secretion ( J:229575 )

• from cultured distal colons of DDS-treated mice after 30 days

increased interleukin-12 secretion ( J:229575 )

• from cultured distal colons of DSS-treated mice after 5 days

• from macrophages following stimulation with LPS, pam3CSK4, MALP2, peptidoglycan (PGN), double-stranded RNA (poly(I:C)), flagellin, loxoribine, or CpG oligo DNA (CpG)

decreased interleukin-13 secretion ( J:229575 )

• from cultured distal colons of DDS-treated mice after 30 days

decreased interleukin-6 secretion ( J:229575 )

• from cultured distal colons of DDS-treated mice after 30 days

increased interleukin-6 secretion ( J:229575 )

• from cultured distal colons of DSS-treated mice after 5 days

• from macrophages following stimulation with LPS, poly(I:C) or loxoribine

increased tumor necrosis factor secretion ( J:229575 )

• from cultured distal colons of DSS-treated mice after 5 and 30 days

• from macrophages following stimulation with LPS, pam3CSK4, double-stranded RNA (poly(I:C)), flagellin, loxoribine, or CpG oligo DNA (CpG)

growth/size/body

increased susceptibility to weight loss ( J:229575 )

• after 5 and 30 days in DSS-treated mice

digestive/alimentary system

decreased colon length ( J:229575 )

• after 5 and 30 days in DDS-treated mice

increased susceptibility to induced colitis ( J:229575 )

• after 5 days, DSS-treated mice exhibit increased mortality, weight loss, bleeding, diarrhea, general loss of architecture, inflammatory cell infiltration, and cytokine production (IL1B, IL6, IL12, IFN-gamma, TNF) compared with wild-type mice

• after 30 days, mice subjected to chronic DDS-induced colitis exhibit decreased B cell infiltration, colon length and cytokine production (IL10, KC, IL6 and IL13) compared with wild-type mice

• however, chronically DSS-treated mice exhibit normal Th1 response

increased susceptibility to colitis induced morbidity/mortality ( J:229575 )

• in DSS-treated mice